{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:30:25Z","timestamp":1758817825891},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s11906-005-0074-4","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:10:51Z","timestamp":1180059051000},"page":"374-378","source":"Crossref","is-referenced-by-count":10,"title":["Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent?"],"prefix":"10.1007","volume":"7","author":[{"given":"Robert D.","family":"Toto","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"74_CR1","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/j.amjhyper.2004.08.003","volume":"17","author":"RD Toto","year":"2004","unstructured":"Toto RD: Lessons learned from recent clinical trials in hypertensive diabetics: What\u2019s good for the kidney is good for the heart and brain. Am J Hypertens 2004, 17:7S-10S.","journal-title":"Am J Hypertens"},{"key":"74_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1524-6175.2004.4064.x","volume":"6","author":"RD Toto","year":"2004","unstructured":"Toto RD: Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 2004, 6:2\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"74_CR3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560\u20132572.","journal-title":"JAMA"},{"key":"74_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"P Gaede","year":"2003","unstructured":"Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383\u2013393.","journal-title":"N Engl J Med"},{"key":"74_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860.","journal-title":"N Engl J Med"},{"key":"74_CR6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861\u2013869. This randomized double-blind placebo-controlled trial demonstrated that the ARB losartan was superior to non-ARB strategy for reducing the risk for ESRD among type 2 diabetics with proteinuria. Moreover, proteinuria reduction was linked to improved outcomes in those randomized to losartan despite similar blood pressure control. This study changed practice.","journal-title":"N Engl J Med"},{"key":"74_CR7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860.","journal-title":"N Engl J Med"},{"key":"74_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker L, Bain R, et al.: The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456\u20131462.","journal-title":"N Engl J Med"},{"key":"74_CR9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/archinte.161.12.1492","volume":"161","author":"R Toto","year":"2001","unstructured":"Toto R: Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 2001, 161:1492\u20131499.","journal-title":"Arch Intern Med"},{"key":"74_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/diab.32.2.S83","volume":"32","author":"H-H Parving","year":"1983","unstructured":"Parving H-H, Andersen AR, Smidt UM, et al.: Diabetic nephropathy and arterial hypertension: The effect of antihypertensive treatment. Diabetes 1983, 32:83\u201387.","journal-title":"Diabetes"},{"key":"74_CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/ajkd.2002.31388","volume":"39","author":"CA Jones","year":"2002","unstructured":"Jones CA, Francis ME, Eberhardt MS, et al.: Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002, 39:445\u2013459.","journal-title":"Am J Kidney Dis"},{"key":"74_CR12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, et al.: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225\u2013232.","journal-title":"Kidney Int"},{"key":"74_CR13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.1997.00440340025002","volume":"157","author":"SF Dinneen","year":"1997","unstructured":"Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997, 157:1413\u20131418.","journal-title":"Arch Intern Med"},{"issue":"Suppl 3","key":"74_CR14","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/dmrr.285","volume":"18","author":"HC Gerstein","year":"2002","unstructured":"Gerstein HC: Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002, 18(Suppl 3):S82-S85.","journal-title":"Diabetes Metab Res Rev"},{"key":"74_CR15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","volume":"139","author":"K Wachtell","year":"2003","unstructured":"Wachtell K, Ibsen H, Olsen MH, et al.: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139:901\u2013906.","journal-title":"Ann Intern Med"},{"key":"74_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","volume":"134","author":"JFE Mann","year":"2001","unstructured":"Mann JFE, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized Trial. Ann Intern Med 2001, 134:629\u2013636.","journal-title":"Ann Intern Med"},{"key":"74_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1464-5491.2001.00548.x","volume":"18","author":"SC Jones","year":"2001","unstructured":"Jones SC, Bowes PD, Hall E, et al.: HOPE for patients with type 2 diabetes: an application of the findings of the MICROHOPE substudy in a British hospital diabetes clinic. Diabet Med 2001, 18:667\u2013670.","journal-title":"Diabet Med"},{"key":"74_CR18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","volume":"351","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P, Fassi A, Ilieva AP, et al.: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941\u20131951. This randomized double-blind placebo controlled trial demonstrated that long-term administration of an ACE inhibitor reduces the risk for new-onset microalbuminuria in type 2 diabetics with normal albumin excretion. It is the primary prevention study using albuminuria as the outcome in patients with diabetes.","journal-title":"N Engl J Med"},{"key":"74_CR19","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","volume":"110","author":"FW Asselbergs","year":"2004","unstructured":"Asselbergs FW, Diercks GF, Hillege HL, et al.: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809\u20132816. In this small double-blind, randomized placebo-controlled trial among microalbuminuric Dutch citizens from the general population, fosinopril treatment was associated with a decrease in albuminuria and a nonsignificant trend toward a decrease in cardiovascular morbidity and mortality. It is the only long-term study attempting to demonstrate a direct benefit of lowering albuminuria.","journal-title":"Circulation"},{"key":"74_CR20","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1111\/j.1523-1755.2004.09224.x","volume":"Suppl","author":"RD Toto","year":"2004","unstructured":"Toto RD: Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int 2004, Suppl:S102-S104.","journal-title":"Kidney Int"},{"key":"74_CR21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, et al.: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139:244\u2013252. This meta-analysis of approximately 1900 nondiabetics with nephropathy demonstrated that lowering systolic blood pressure to the 120 to 130 mm Hg range among those with urine protein excretion of \u2265 1 g\/d was associated with a lower risk for end-stage renal disease. These results helped shape clinical practice guidelines for blood pressure control in patients with chronic kidney disease.","journal-title":"Ann Intern Med"},{"key":"74_CR22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","volume":"63","author":"W Keane","year":"2003","unstructured":"Keane W, Brenner B, deZeeuw D, et al.: The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003, 63:1499\u20131507.","journal-title":"Kidney Int"},{"key":"74_CR23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921\u2013927.","journal-title":"Circulation"},{"key":"74_CR24","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","volume":"65","author":"D Zeeuw de","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309\u20132320.","journal-title":"Kidney Int"},{"key":"74_CR25","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421\u20132431.","journal-title":"JAMA"},{"key":"74_CR26","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, et al.: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285:2719\u20132728.","journal-title":"JAMA"},{"key":"74_CR27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensinconverting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117\u2013124.","journal-title":"Lancet"},{"key":"74_CR28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archinte.1993.00410080037006","volume":"153","author":"R Slataper","year":"1993","unstructured":"Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993, 153:973\u2013980.","journal-title":"Arch Intern Med"},{"key":"74_CR29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1523-1755.1998.00055.x","volume":"54","author":"AC Smith","year":"1998","unstructured":"Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998, 54:889\u2013896.","journal-title":"Kidney Int"},{"key":"74_CR30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1523-1755.1998.00083.x","volume":"54","author":"GL Bakris","year":"1998","unstructured":"Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor\/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998, 54:1283\u20131289.","journal-title":"Kidney Int"},{"key":"74_CR31","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.V9112096","volume":"9","author":"P Ruggenenti","year":"1998","unstructured":"Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensinconverting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998, 9:2096\u20132101.","journal-title":"J Am Soc Nephrol"},{"key":"74_CR32","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","volume":"65","author":"GL Bakris","year":"2004","unstructured":"Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991\u20132002. This review identified nondihydropyridine compared to dihydropyridine calcium channel blockers as superior for lowering proteinuria in patients with chronic kidney disease.","journal-title":"Kidney Int"},{"key":"74_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.ajkd.2004.03.003","volume":"43","author":"Kidney Disease Outcomes Quality Initiative","year":"2004","unstructured":"Kidney Disease Outcomes Quality Initiative: K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:11\u201313.","journal-title":"Am J Kidney Dis"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0074-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-005-0074-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-005-0074-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:04:35Z","timestamp":1628917475000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-005-0074-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s11906-005-0074-4","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}